The market for digital therapeutics (DTx) is expanding tremendously, aided by the increased popularity of decentralized medicine that the pandemic brought about. The global market for DTx was predicted to be worth $3.35 billion in 2021 and would grow to $12.1 billion by 2026.
Last month, the Biden-Harris Administration took a new stance on healthcare costs rising exponentially across the US by signing the Inflation Reduction Act (IRA). IRA passage with provisions aiming to reduce out-of-pocket costs is truly the capstone achievement.
Care delivery models are taking a paradigm shift with the advent of novel technology solutions across the healthcare and life sciences industry. AI and ML applications are partly to take credit in this transformation which has facilitated delivery of high-quality care services more conveniently.
Large incisions have been used by surgeons for generations to perform surgery, introduce the required surgical equipment, and get a complete view of the organ they needed to treat. The new era of robotic surgery has come into the limelight in the last two decades.
Healthcare providers are moving the needle in the healthcare delivery landscape with the advent of digital health and technology solutions. Momentum around digital transformation continues to build, which aims to enhance consumer engagement and patient access.
With the prevalence of fatal diseases escalating across disease areas, digital therapeutics have played a pivotal role in catering to patients outside of hospital setups. DTx has emerged as a novel category of medical interventions that are poised to disrupt the traditional care delivery spectrum.
Pandemic-infused demand for remote care solutions has grown dramatically in recent times, medical devices being the cornerstone in this area. With these devices instituting a paradigm shift in care delivery models, we undertook a critical assessment of Medical Device Markets and attempted to determine the key innovations.
The globalization of China's life science sector analyzes the Chinese government's backing for the healthcare industry and its effects on global political and economic ties as well as on worldwide scientific innovation.
New technological innovations are improving the efficiency and productivity of clinical trials using novel outcomes, increasing patient engagement, and reducing patient burden.
Transformations in care delivery models have propelled providers and payers to foster collaborations that will not only impact the quality of the care but also enhance their financial stability. These collaborations are majorly value-driven that partly contributes to social determinants of health and overall enhances patient health.
As the entire world healthcare system is recovering from the impact of COVID – 19, it is constantly evolving for providing better patient care and medical services. Advancement in technologies such as AI, cloud computing, robotics, EHR will seem to take over the trends for the upcoming year as personalized treatments and customized solutions have shown to make their way into the healthcare system.
Pharma's reputation may have improved during the pandemic, but that also meant that diversity, equity, and inclusion (DEI) issues were given more attention. Pharma companies have mostly concentrated on equality in recent years, but this new era of health equity is needed to address the expanding population's DEI challenges.
Even though mRNA therapies have recently generated a lot of hype, few businesses have been able to advance their concepts and turn science into clinical reality. Vaccines have been used to prevent diseases including COVID-19, polio, and smallpox for ages.
The medical sector's innovations drive ongoing change in the healthcare technology sector. From MRI scans and X-rays to robotic surgery and virtual reality, the healthcare industry is undergoing a significant digital shift.
Russia’s invasion of Ukraine had a negative influence on healthcare. The economy, infrastructure, and society, healthcare systems suffer greatly as a result of the interruption.
Entrepreneur Ida Tin originally used the term "Femtech" in 2016. It has expanded over the course of just a few years to include a variety of technologically enabled consumer-focused products and solutions.